Because approximately 45% of cancer cell lines are SLFN11-negative at the transcript level [23, 25], frequently by promoter hypermethylation [24], SLFN11 can be considered a testable biomarker to predict responders to PARPIs in addition to BRCA mutations and HRD. The gene discussed is SLFN11; the disease is cancer.